master's thesis
Terapijske mogućnosti liječenja karcinoma pluća malih stanica

Monika Krušlin (2016)
Sveučilište u Rijeci
Medicinski fakultet
Katedra za onkologiju i radioterapiju
Metadata
TitleTerapijske mogućnosti liječenja karcinoma pluća malih stanica
AuthorMonika Krušlin
Mentor(s)Marija Petković (thesis advisor)
Abstract
Karcinom pluća je najčešći karcinom u oba spola. Glavni uzrok u većini slučajeva karcinoma pluća jest konzumacija duhanskih proizvoda. Mali dio karcinoma pluća uzrokuju tvari na koje se udišu pri radu, kao što su azbest i nikal. SCLC čini 20% karcinoma pluća. Pacijenti sa SCLC-om se liječe primarno kemoterapijom, jer je SCLC dobro osjetljiv na kemoterapiju i jer je SCLC najčešće već u vrijeme dijagnoze proširen po organizmu. SCLC se dijeli na ograničeni i prošireni stadij. Ograničeni stadij jest kad je karcinom lokaliziran u jednom hemitoraksu, a prošireni stadij označava bolest kad je karcinom proširen izvan jednog hemitoraksa. Kirurgija ne igra važnu ulogu u liječenju jer se većina SCLC-a otkrije u proširenom stadiju. U pacijenata s ograničenim stadijem bolesti, uz kemoterapiju se provodi istovremena radioterapija, dok se kod pacijenata sa proširenim stadijem provodi samo kemoterapija. Najčešće korištena kombinacija citotoksičnih lijekova je etopozid i cistplatin. Kemoterapija se provodi između 4 do 6 ciklusa. SCLC ima sklonost širenja u mozak, pa se kod većine pacijenata provodi profilaktičko zračenje mozga s ciljem sprečavanja metastaza u mozgu. U većini pacijenata nakon nekog vremena pojavi se recidiv SCLC. Topotekan je izbor lijeka u liječenju recidiva SCLC. Prognoza je vrlo loša, stopa petogodišnjeg preživljenja kod ograničenog stadija je 20 mjeseci, a kod pacijenata s proširenim stadijem, između 7 i 11 mjeseci.
Keywordssmall cell lung cancer chemotherapy radiotherapy etoposide cistplatin
Committee MembersIngrid Belac-Lovasić (committee chairperson)
Ines Mrakovčić-Šutić (committee member)
Ivana Marić (committee member)
GranterSveučilište u Rijeci
Medicinski fakultet
Lower level organizational unitsKatedra za onkologiju i radioterapiju
PlaceRijeka
StateCroatia
Scientific field, discipline, subdisciplineBIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Study programme typeuniversity
Study levelintegrated undergraduate and graduate
Study programmeMedicine
Academic title abbreviationdr. med.
Genremaster's thesis
Language Croatian
Defense date2016-07-15
Parallel abstract (English)
Lung cancer is the most common cancer in men and women. The main cause of most cases of lung cancer is the consumption of tobacco products. A small fraction of lung cancer is caused by substances that are inhaled during work, such as asbestos and nickel. SCLC accounts for 20% of lung cancer. Primary, patients with SCLC are treated with chemotherapy because it is well-sensitive to chemotherapy and at the time of diagnosis SCLC is usually augmented through the body. SCLC is divided into limited-stage and extensive-stage. Limited stage SCLC is confined to one hemithorax and extended stage in SCLC is extended beyond one hemithorax. Surgery doesn't have an important role in the treatment of SCLC because most times SCLC is detected in the extended stage. In patients with limited-stage disease, chemotherapy with radiation therapy is performed simultaneously, while in patients with an extended stage only chemotherapy is carried out. The most commonly used combination of cytotoxic drugs is etoposide and cistplatin. Chemotherapy is carried out between 4 to 6 cycles. SCLC tends to spread to the brain, so most patients get prophylactic brain radiation to prevent metastases in the brain. In most patients a relapse of SCLC appears. Topotecan is the drug of choice in the treatment of relapse SCLC. The prognosis is very poor, the survival rate in those with the limited stage is 20 months, and in patients with extended stage, it's between 7 and 11 months.
Parallel keywords (Croatian)karcinom pluća malih stanica kemoterapija radioterapija etopozid cistplatin
Resource typetext
Access conditionAccess restricted to students and staff of home institution
Terms of usehttp://rightsstatements.org/vocab/InC/1.0/
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:184:053549
CommitterBosa Licul